Berobenatide: how it enters the blood after different delivery methods in adults with overweight or obesity

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1 interventional trial explores how Berobenatide is absorbed and tolerated when administered via different delivery systems in adults with BMI 27-45 kg/m2. Participants will have multiple clinic visits for a single-dose administration and safety monitoring. The study focuses on safety and pharmacokinetics to understand how the drug enters the bloodstream and its initial effects. Lead sponsor is Pfizer, with Anaheim Clinical Trials, LLC as the site in California.

Why it matters

Who can join: the full rules

Key Inclusion Criteria:

* Participants 18 years of age or older
* BMI of 27-45 kg/m2; and a total body weight \>50 kg (110 lb)

Key Exclusion Criteria:

* Pregnant or breastfeeding women, or those planning pregnancy during the study
* History of other chronic disorders
* Personal or first-degree family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2), or suspected MTC
* Clinically significant gastric emptying abnormality or chronically taking drugs that directly affect gastrointestinal (GI) motility
* Acute GI symptoms at screening, Day -1, or prior to administration of study intervention

Where it's running

• Anaheim Clinical Trials, LLC
  Anaheim, California, United States Recruiting

Study contacts

• Study coordinator: Pfizer CT.gov Call Center
• Email: ClinicalTrials.gov_Inquiries@pfizer.com
• Phone: 1-800-718-1021

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese

  This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).

  Recruiting Phase 3 Pfizer · Birmingham, Alabama and 3 other locations · NCT07915609

• Berobenatide in adults with sleep apnea and obesity who don’t use a PAP machine

  This study tests berobenatide versus placebo in adults with moderate-to-severe obstructive sleep apnea and overweight or obesity who are not using PAP therapy.

  Recruiting at 3 sites Phase 3 Pfizer · Cullman, Alabama and 3 other locations · NCT07881757

• Switching to a monthly dose of Berobenatide to help keep weight off after weight loss with semaglutide or tirzepatide

  This study tests whether switching to a monthly berobenatide shot can help adults who have overweight or obesity and have already lost weight using semaglutide or tirzepatide to keep the weight off.

  Recruiting at 18 sites Phase 3 Pfizer · Birmingham, Alabama and 25 other locations · NCT07845500

• Berobenatide in adults with sleep apnea and obesity using a PAP machine

  This study tests berobenatide vs. placebo in adults with moderate to severe obstructive sleep apnea and overweight/obesity who use a PAP device.

  Recruiting at 6 sites Phase 3 Pfizer · Cullman, Alabama and 7 other locations · NCT07823608

• Body- or Mind-based regulation in women with overweight or obesity

  This study tests whether a body-based regulation program or a mind-based regulation program helps women with overweight or obesity improve heart rate regulation and emotional eating.

  Recruiting Pamukkale University · Denizli · NCT07738263

• Semaglutide delivered by a needle-free skin patch versus injections in adults with overweight or obesity

  This early study tests a needle-free skin patch delivering semaglutide against standard injections in adults who are overweight or obese to see if the patch works safely and as well as injections.

  Recruiting Phase 1 Terrestrial Bio, Inc. · Tempe, Arizona · NCT07673900

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.